Cara Therapeutic Stock In The News

CARA Stock  USD 5.00  0.03  0.60%   
Our overall analysis of Cara Therapeutic's news coverage and content from conventional and social sources shows investors' bearish mood towards Cara Therapeutic. The specific impact of Cara Therapeutic news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Cara Therapeutic's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Cara Therapeutic headlines in addition to utilizing other, more conventional financial analysis modules. Check out Cara Therapeutic Backtesting and Cara Therapeutic Hype Analysis.
For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.

Cara Therapeutic Today Top News and Investor Outlook

Yahoo News
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
https://finance.yahoo.com/news/cara-therapeutics-prioritizes-stage-notalgia-120000424.html
 Neutral
Yahoo News
CARA's Late-Stage Skin Disease Study Fails, Stock Plummets 49%
https://finance.yahoo.com/news/caras-stage-skin-disease-study-165500921.html
 Bullish
Yahoo News
Cara Therapeutics Announces Outcome from...
https://finance.yahoo.com/news/cara-therapeutics-announces-outcome-dose-120000127.html
 Neutral
Yahoo News
Cara Therapeutics, Inc. (NASDAQ:CARA) Q3 2023 Earnings Call Transcript
https://finance.yahoo.com/news/cara-therapeutics-inc-nasdaq-cara-160416028.html
 Bullish
Yahoo News
Q3 2023 Cara Therapeutics Inc Earnings Call
https://finance.yahoo.com/news/q3-2023-cara-therapeutics-inc-134816183.html
 Bullish
Yahoo News
Cara (CARA) Reports Q3 Earnings: What Key Metrics Have to Say
https://finance.yahoo.com/news/cara-cara-reports-q3-earnings-230003858.html
 Bullish
Macroaxis News: globenewswire.com
Cara Therapeutics Reports Third Quarter 2023 Financial Results
https://www.globenewswire.com/news-release/2023/11/13/2779412/29236/en/Cara-Therapeutics-Reports-Third-Quarter-2023-Financial-Results.html
 Bullish
Yahoo News
Cara Therapeutics Reports Third Quarter 2023 Financial Results
https://finance.yahoo.com/news/cara-therapeutics-reports-third-quarter-210100881.html
 Bullish
Yahoo News
These Biotech Stocks Could Double Your Money, According To Analysts
https://finance.yahoo.com/news/biotech-stocks-could-double-money-163853459.html
 Bullish
Yahoo News
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
https://finance.yahoo.com/news/pliant-therapeutics-inc-plrx-expected-150007706.html
 Bullish

Cara Therapeutic Past News Timeline

From Feb 24 to Nov 23Use up and down arrows to move selectionTo Feb 24Use up and down arrows to move upper selectionFrom Nov 23Use up and down arrows to move lower selectionUse TAB select grip buttons or up and down arrows to change selection100%
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Cara and other traded companies coverage with news coverage. We help investors stay connected with Cara headlines for the 24th of February to make an informed investment decision based on correlating the impacts of news items on Cara Stock performance. Please note that trading solely based on the Cara Therapeutic hype is not for everyone as timely availability and quick action are needed to avoid losses.
Cara Therapeutic's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Cara Therapeutic investors visualize upcoming and past events in order to time the market based on Cara Therapeutic noise-free hype analysis.
Cara Therapeutic stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Cara earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Cara Therapeutic that are available to investors today. That information is available publicly through Cara media outlets and privately through word of mouth or via Cara internal channels. However, regardless of the origin, that massive amount of Cara data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cara Therapeutic news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cara Therapeutic relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cara Therapeutic's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cara Therapeutic alpha.

Cara Largest EPS Surprises

Earnings surprises can significantly impact Cara Therapeutic's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2017-11-02
2017-09-30-0.34-0.38-0.0411 
2016-11-03
2016-09-30-0.47-0.420.0510 
2019-03-12
2018-12-31-0.58-0.520.0610 
2016-08-04
2016-06-30-0.42-0.48-0.0614 
2015-05-12
2015-03-31-0.27-0.210.0622 
2014-08-07
2014-06-30-0.22-0.160.0627 
View All Earnings Estimates

Cara Therapeutic Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Cara Therapeutic Stock. Current markets are slightly bearish. About 55% of major world exchanges and indexes are down. See today's market update for more information.
Google News at Macroaxis
7th of February 2025
Cara Therapeutics CEO Christopher Posner sells 1,755 in stock By Investing.com - Investing...
at news.google.com 
Google News at Macroaxis
17th of January 2025
Cara Therapeutics Begin Trading On Reverse Split-Adjusted Basis - Nasdaq
at news.google.com 
Gurufocus Stories at Macroaxis
27th of December 2024
Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split
at gurufocus.com 
news
26th of December 2024
Cara Therapeutics Research Coverage Started at StockNews.com
at thelincolnianonline.com 
businesswire News
18th of December 2024
CARA Stock Alert Halper Sadeh LLC Is Investigating Whether the Merger of Cara Therapeutics...
at businesswire.com 
news
2nd of December 2024
StockNews.com Initiates Coverage on Cara Therapeutics
at thelincolnianonline.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cara Therapeutic in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cara Therapeutic's short interest history, or implied volatility extrapolated from Cara Therapeutic options trading.
When determining whether Cara Therapeutic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cara Therapeutic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cara Therapeutic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cara Therapeutic Stock:
Check out Cara Therapeutic Backtesting and Cara Therapeutic Hype Analysis.
For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(21.00)
Revenue Per Share
1.907
Quarterly Revenue Growth
(0.47)
Return On Assets
(0.62)
Return On Equity
(2.21)
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
News Freq…Investor S…